Popular terms

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      

This page is updated frequently with new Cytokine-related patent applications.




Date/App# patent app List of recent Cytokine-related patents
05/19/16
20160136205 
 Targeting type i nkt cells to control inflammation patent thumbnailnew patent Targeting type i nkt cells to control inflammation
Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen.. .
The Board Of Regents Of The University Of Texas System


05/19/16
20160136204 
 Production and therapeutic uses of th1-like regulatory t cells patent thumbnailnew patent Production and therapeutic uses of th1-like regulatory t cells
A unique cd4+cd25+ regulatory t cell population develops from naive cd4+cd25− t cells during a th1 polarized immune response (called th1-tr cells). These th1-tr cells can be generated by contacting naïve t cells with mature cd8α+ dendritic cells (dcs) that have been exposed to a th1 polarizing adjuvant and, in some cases, an antigen of interest.
The Board Of Trustees Of The Leland Stanford Junior University


05/12/16
20160131663 
 Biomarker for psychiatric and neurological disorders patent thumbnailBiomarker for psychiatric and neurological disorders
The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.


05/12/16
20160130357 
 Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same patent thumbnailCompositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


05/12/16
20160129110 
 Immunoprotective primary mesenchymal stem cells and methods patent thumbnailImmunoprotective primary mesenchymal stem cells and methods
Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
The Administrators Of The Tulane Educational Fund


05/12/16
20160129109 
 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer patent thumbnailUniversal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore


05/05/16
20160120970 
 Compounds and methods for affecting cytokines patent thumbnailCompounds and methods for affecting cytokines
The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of tnf-a, lactoferrin, ifn-γ, il-i β, serum amyloid-a (saa), il-6 and/or β-defensin associated with infection or an immune response generally..
Zivo Biosciences, Inc.


04/28/16
20160116484 
 Systems and methods for characterizing kidney diseases patent thumbnailSystems and methods for characterizing kidney diseases
The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine.
Renovar Incorporated


04/28/16
20160116469 
 Immunologically active polypeptide patent thumbnailImmunologically active polypeptide
Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115227 
 Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease patent thumbnailAdministration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject.

04/28/16
20160114078 

Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate


The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component.
Spinesmith Partners, L.p.


04/28/16
20160114008 

Methods for accelerating the healing of connective tissue injuries and disorders


The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments.
Stemnion, Inc.


04/21/16
20160108108 

Inflammatory disease diagnosis and methods of treatment using lipopolysaccharides-responsive beige-like anchor


Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable.

04/21/16
20160108101 

Recombinant cancer therapeutic cytokine


Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of mda-7/tl-24 (“m4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to mda-7/il-24 receptors on adjacent, neighboring and distant cancer cells.

04/21/16
20160106887 

Medical device


The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..

04/21/16
20160106832 

Treatment of cancer with naltrexone


The present invention provides novel therapeutic applications of low dose naltrexone (ldn). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of toll-like receptor 9 (tlr9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized.

04/14/16
20160101132 

Enhanced anabolic cytokine production and delivery system


Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).

04/07/16
20160095954 

Fibrin microthreads


Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute


04/07/16
20160095912 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095911 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095892 

Sour cherry topical biotherapeutic formulations, manufacture and treatment of human osteoarthritis symptoms


A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by cd3+ t lymphocytes in a vertebrate mammal.. .

03/31/16
20160091486 

Glatiramer acetate human monocytic cell line-based potency assay


The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (ifnγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sil-1ra or the viability of said cells induced by glatiramer acetate.. .
Synthon B.v.


03/31/16
20160089426 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089425 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089424 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/24/16
20160083442 

Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use


In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160082092 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh


03/24/16
20160082085 

Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer


The present invention relates to a combination of a parvovirus and a cytokine, preferably ifny, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
Ruprecht-karls-universitaet Heidelberg


03/24/16
20160081958 

Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response


Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (mso). The mso may be l-methionine s-sulfoximine (lsmso), l-methionine r-sulfoximine (lrmso), or diastereomeric mixture of lsmso and lrmso.

03/24/16
20160081913 

Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and producing same


The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (nscs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.
Korea University Research And Business Foundation


03/24/16
20160081329 

Modulating ischemic injury and preserving/storing tissue


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.


03/17/16
20160077107 

Personalised medicine


The present invention relates to a method for assessing the efficacy of an inhibitor of a pro-inflammatory cytokine and/or of b cells in a subject and a method for treating said subject with said inhibitor provided the efficacy of said inhibitor has been determined as sufficient.. .
Stichting Katholieke Universiteit


03/17/16
20160077102 

Diagnostic biomarker to predict women at risk for preterm delivery


The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery.
Cedars-sinai Medical Center


03/17/16
20160075996 

Method for producing nk cell-enriched blood preparation


It is intended to provide a method for producing an nk cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing nk cells, etc. In blood collected from an organism.
Biotherapy Institute Of Japan


03/17/16
20160075739 

Peptide for inducing mast cell-specific apoptosis and use thereof


A peptide according to the present invention can perform a function identical or similar to the function of natural ctla-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (cd80 and cd86) to inhibit activity of t cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, il-2 and ifn-γ).
Caregen Co., Ltd.


03/17/16
20160074537 

Immunoconjugates for the treatment of tumours


A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (ttm) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.. .
Molmed Spa


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074437 

Immunological treatment of liver failure


Disclosed are means of treatment of liver failure and augmentation of liver regeneration by utilization of immune modulation through administration of immunocytes and mesenchymal stem cells. In one embodiment liver failure is treated by cord blood mononuclear cells administered allogeneic to the host that have been pretreated with hepatogenic cytokines..
Batu Biologics, Inc.


03/10/16
20160070884 

Systems and methods for detecting infectious diseases


Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.


03/10/16
20160069882 

Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis


The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases.
Albert-ludwigs-universitÄt Freiburg


03/10/16
20160068584 

Cytokine derived treatment with reduced vascular leak syndrome


The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an il-15 derivative conjugate so as to induce a proliferation of natural killer cells (nk cells) which is the same or higher than the one obtained with high dose of interleukin-2 (hdil-2); eventually associated with a pharmaceutically acceptable carrier.. .
Institut Gustave Roussy (igr)


03/10/16
20160067357 

Detection of high risk drusen


In some aspects, methods of detecting complement activation in vivo, e.g., in an eye, are provided. In some aspects, methods of detecting high risk drusen are provided.
Apellis Pharmaceuticals, Inc.


03/10/16
20160067356 

Genetically modified human natural killer cell lines


The invention provides a natural killer cell, nk-92, modified to express an fc receptor on the surface of the cell, such as cd 16 (fcγriii-a), or other fcγ or fc receptors. The modified nk-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as fcεri-γ,tcr-ζ, or to concurrently express interleukin-2 (il-2) or other cytokines.
Fox Chase Cancer Center


03/10/16
20160067284 

Method for producing sheet-shaped cell culture


A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture.
Terumo Kabushiki Kaisha


03/10/16
20160067270 

Use of ginsenoside f2 for prophylaxis and treatment of liver disease


Provided are use of ginsenoside f2 in the prevention, improvement or treatment of liver disease, and a pharmaceutical composition, a health functional food, and a feed composition including ginsenoside f2. Ginsenoside f2 inhibits fat synthesis and accumulation in the liver, and increases distribution of regulatory t cells capable of inhibiting activity of inflammatory cells, thereby preventing hepatitis, and also increases expression of anti-inflammatory cytokine il-10 in regulatory t cells, and inhibits differentiation of naive t cells into th17 cells, and is thereby effectively used for the treatment of various liver diseases..
Intelligent Synthetic Biology Center


03/03/16
20160060323 

Zcytor17 heterodimeric cytokine receptor


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060313 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-angiogenic effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-angiogenic compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.


03/03/16
20160058835 

Use of taenia solium recombinant calreticulin for inducing interleukin-10 expression


The present invention is related to the use of a recombinant protein to induce interleukin 10 expression, wherein the protein is taenia solium parasite recombinant calreticulin (rtscrt) formulated in a physiologic glycosated solution orally or parenterally administered. The used methodology for rtscrt expression and purification described in present invention, resulted in a recombinant protein expressed without post-translational modifications having regulatory immunological effects and capable of stimulating the mrna transcription levels which codify for il-4 and il-10 cytokines.
Universidad Nacional AutÓnoma De MÉxico


03/03/16
20160058798 

Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree


A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.
University Of Miami


02/25/16
20160053008 

Antibodies that bind both il-17a and il-17f and methods of using same


The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc.


02/25/16
20160051642 

Treatment of peyronie's disease


The invention relates to systems and therapeutic methods to reduce plaque causing peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque.
Ams Research, Llc


02/18/16
20160047795 

In vitro assessing cytokine storm responses


The present disclosure an in vitro method of assaying the stimulation of a cytokine storm response comprising the steps of: a. Co-culturing pbmcs and matched differentiated endothelial cells to provide a system representative of human responses in vivo, and b.
Imperial Innovations Ltd


02/18/16
20160046710 

Notch2 binding molecules for treating respiratory diseases


The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease.
Novartis Ag


02/18/16
20160046611 

Novel chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders


The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4h-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines.
Council Of Scientific & Industrial Research


02/18/16
20160045597 

Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1


The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human cd40; and a pd-l1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.. .
Hoffmann-la Roche Inc.


02/18/16
20160045548 

Method for treating cancers with dendritic killer cells and pharmaceutical composition comprising the same


The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is il-15.
Fullhope Biomedical Co., Ltd


02/18/16
20160045517 

Treating auto-immune and auto-inflammatory diseases


The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (il-17 or il-17a) levels in both broncheoalveolar lavage fluid (balf) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (mapk) activity involving the use of 17α-hydroxyprogesterone caproate (17-ohpc) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-ohpc, and the formulation may be used in a method to treat il-17 cytokine and/or p38 mapk mediated auto-immune and auto-inflammatory diseases.
Prairie Pharmaceuticals Llc


02/18/16
20160045396 

Pulmonary delivery of progestogen


The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-ohpc) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-ohpc as taught herein may be used to reduce cytokine interleukin-17 (il-17 or il-17a) levels in both broncheoalveolar lavage fluid (balf) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (mapk) activity.
Prairie Pharmaceuticals Llc




Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6344

4654

469293 - 0 - 105